AAPL338.19-1.89 (-0.56%) ▼|ABBV263.30+0.10 (+0.04%) ▲|ABT108.00+0.73 (+0.68%) ▲|ACN173.17+8.51 (+5.17%) ▲|ADBE263.43+14.25 (+5.72%) ▲|AMAT436.45-40.01 (-8.40%) ▼|AMD429.56-25.06 (-5.51%) ▼|AMGN387.64-5.46 (-1.39%) ▼|AMT179.26+7.76 (+4.52%) ▲|AMZN226.65-4.21 (-1.82%) ▼|AVGO370.32-10.59 (-2.78%) ▼|AXP331.50-5.13 (-1.52%) ▼|BA214.01-7.55 (-3.41%) ▼|BAC61.07-1.55 (-2.48%) ▼|BKNG201.30+1.99 (+1.00%) ▲|BLK1,079.19-18.36 (-1.67%) ▼|BMY63.10-0.50 (-0.79%) ▼|BNY152.50-3.99 (-2.55%) ▼|BRK-B509.16-3.21 (-0.63%) ▼|C127.13-5.34 (-4.03%) ▼|CAT782.71-58.14 (-6.91%) ▼|CL93.49+0.76 (+0.82%) ▲|CMCSA24.61+0.42 (+1.74%) ▲|COF208.71-3.70 (-1.74%) ▼|COP118.06+3.96 (+3.47%) ▲|COST974.03+7.45 (+0.77%) ▲|CRM188.38+6.88 (+3.79%) ▲|CSCO112.48-3.10 (-2.68%) ▼|CVS105.92-3.42 (-3.13%) ▼|CVX191.86+4.28 (+2.28%) ▲|DE610.95-28.89 (-4.52%) ▼|DHR196.49-2.56 (-1.29%) ▼|DIS98.48-0.41 (-0.41%) ▼|DUK129.08-0.16 (-0.12%) ▼|EMR145.73-6.08 (-4.01%) ▼|FDX308.61-4.03 (-1.29%) ▼|GD380.96-12.23 (-3.11%) ▼|GE350.63-12.96 (-3.56%) ▼|GEV900.28-43.10 (-4.57%) ▼|GILD132.73-1.59 (-1.18%) ▼|GM89.40-0.90 (-1.00%) ▼|GOOG335.76+3.16 (+0.95%) ▲|GOOGL336.71+3.00 (+0.90%) ▲|GS980.75-52.59 (-5.09%) ▼|HD338.27-6.20 (-1.80%) ▼|HON241.12-5.93 (-2.40%) ▼|IBM226.44-1.11 (-0.49%) ▼|INTC81.88-4.42 (-5.12%) ▼|INTU333.13+20.14 (+6.43%) ▲|ISRG353.10-8.70 (-2.40%) ▼|JNJ265.53-1.20 (-0.45%) ▼|JPM344.71-12.60 (-3.53%) ▼|KO89.08+0.81 (+0.92%) ▲|LIN511.17-0.01 (0.00%) ▼|LLY1,210.02-10.64 (-0.87%) ▼|LMT569.20-12.11 (-2.08%) ▼|LOW215.68-2.56 (-1.17%) ▼|LRCX252.35-17.26 (-6.40%) ▼|MA563.32+0.57 (+0.10%) ▲|MCD271.52-1.50 (-0.55%) ▼|MDLZ64.99+2.51 (+4.02%) ▲|MDT87.54+0.66 (+0.76%) ▲|META585.61-7.80 (-1.31%) ▼|MMM177.95-4.53 (-2.48%) ▼|MO74.92+0.10 (+0.13%) ▲|MRK130.36-1.46 (-1.11%) ▼|MS203.13-8.45 (-3.99%) ▼|MSFT390.54-2.81 (-0.71%) ▼|MU739.00-81.53 (-9.94%) ▼|NEE88.46-0.82 (-0.92%) ▼|NFLX73.63+1.24 (+1.71%) ▲|NKE43.22+0.17 (+0.39%) ▲|NOW115.76+5.14 (+4.65%) ▲|NVDA190.01-7.00 (-3.55%) ▼|ORCL117.74-2.22 (-1.85%) ▼|PEP143.50+0.64 (+0.45%) ▲|PFE25.15-0.10 (-0.40%) ▼|PG146.10-2.78 (-1.87%) ▼|PLTR123.00-0.53 (-0.43%) ▼|PM198.44-1.73 (-0.86%) ▼|QCOM155.68-7.20 (-4.42%) ▼|RTX215.25-3.33 (-1.52%) ▼|SBUX104.14+1.04 (+1.01%) ▲|SCHW104.47-1.50 (-1.42%) ▼|SO96.05-0.73 (-0.75%) ▼|SPG235.61-1.09 (-0.46%) ▼|T23.94-0.72 (-2.92%) ▼|TMO576.46+0.05 (+0.01%) ▲|TMUS181.52-0.87 (-0.48%) ▼|TSLA298.32-9.12 (-2.97%) ▼|TXN271.30-5.77 (-2.08%) ▼|UBER71.20+0.46 (+0.65%) ▲|UNH420.57-8.22 (-1.92%) ▼|UNP292.19-2.26 (-0.77%) ▼|UPS104.56-0.97 (-0.92%) ▼|USB62.82-1.61 (-2.50%) ▼|V368.73+2.14 (+0.58%) ▲|VZ47.22-0.97 (-2.01%) ▼|WFC83.87-3.00 (-3.45%) ▼|WMT114.22+1.12 (+0.99%) ▲|XOM156.75+3.71 (+2.42%) ▲|AAPL338.19-1.89 (-0.56%) ▼|ABBV263.30+0.10 (+0.04%) ▲|ABT108.00+0.73 (+0.68%) ▲|ACN173.17+8.51 (+5.17%) ▲|ADBE263.43+14.25 (+5.72%) ▲|AMAT436.45-40.01 (-8.40%) ▼|AMD429.56-25.06 (-5.51%) ▼|AMGN387.64-5.46 (-1.39%) ▼|AMT179.26+7.76 (+4.52%) ▲|AMZN226.65-4.21 (-1.82%) ▼|AVGO370.32-10.59 (-2.78%) ▼|AXP331.50-5.13 (-1.52%) ▼|BA214.01-7.55 (-3.41%) ▼|BAC61.07-1.55 (-2.48%) ▼|BKNG201.30+1.99 (+1.00%) ▲|BLK1,079.19-18.36 (-1.67%) ▼|BMY63.10-0.50 (-0.79%) ▼|BNY152.50-3.99 (-2.55%) ▼|BRK-B509.16-3.21 (-0.63%) ▼|C127.13-5.34 (-4.03%) ▼|CAT782.71-58.14 (-6.91%) ▼|CL93.49+0.76 (+0.82%) ▲|CMCSA24.61+0.42 (+1.74%) ▲|COF208.71-3.70 (-1.74%) ▼|COP118.06+3.96 (+3.47%) ▲|COST974.03+7.45 (+0.77%) ▲|CRM188.38+6.88 (+3.79%) ▲|CSCO112.48-3.10 (-2.68%) ▼|CVS105.92-3.42 (-3.13%) ▼|CVX191.86+4.28 (+2.28%) ▲|DE610.95-28.89 (-4.52%) ▼|DHR196.49-2.56 (-1.29%) ▼|DIS98.48-0.41 (-0.41%) ▼|DUK129.08-0.16 (-0.12%) ▼|EMR145.73-6.08 (-4.01%) ▼|FDX308.61-4.03 (-1.29%) ▼|GD380.96-12.23 (-3.11%) ▼|GE350.63-12.96 (-3.56%) ▼|GEV900.28-43.10 (-4.57%) ▼|GILD132.73-1.59 (-1.18%) ▼|GM89.40-0.90 (-1.00%) ▼|GOOG335.76+3.16 (+0.95%) ▲|GOOGL336.71+3.00 (+0.90%) ▲|GS980.75-52.59 (-5.09%) ▼|HD338.27-6.20 (-1.80%) ▼|HON241.12-5.93 (-2.40%) ▼|IBM226.44-1.11 (-0.49%) ▼|INTC81.88-4.42 (-5.12%) ▼|INTU333.13+20.14 (+6.43%) ▲|ISRG353.10-8.70 (-2.40%) ▼|JNJ265.53-1.20 (-0.45%) ▼|JPM344.71-12.60 (-3.53%) ▼|KO89.08+0.81 (+0.92%) ▲|LIN511.17-0.01 (0.00%) ▼|LLY1,210.02-10.64 (-0.87%) ▼|LMT569.20-12.11 (-2.08%) ▼|LOW215.68-2.56 (-1.17%) ▼|LRCX252.35-17.26 (-6.40%) ▼|MA563.32+0.57 (+0.10%) ▲|MCD271.52-1.50 (-0.55%) ▼|MDLZ64.99+2.51 (+4.02%) ▲|MDT87.54+0.66 (+0.76%) ▲|META585.61-7.80 (-1.31%) ▼|MMM177.95-4.53 (-2.48%) ▼|MO74.92+0.10 (+0.13%) ▲|MRK130.36-1.46 (-1.11%) ▼|MS203.13-8.45 (-3.99%) ▼|MSFT390.54-2.81 (-0.71%) ▼|MU739.00-81.53 (-9.94%) ▼|NEE88.46-0.82 (-0.92%) ▼|NFLX73.63+1.24 (+1.71%) ▲|NKE43.22+0.17 (+0.39%) ▲|NOW115.76+5.14 (+4.65%) ▲|NVDA190.01-7.00 (-3.55%) ▼|ORCL117.74-2.22 (-1.85%) ▼|PEP143.50+0.64 (+0.45%) ▲|PFE25.15-0.10 (-0.40%) ▼|PG146.10-2.78 (-1.87%) ▼|PLTR123.00-0.53 (-0.43%) ▼|PM198.44-1.73 (-0.86%) ▼|QCOM155.68-7.20 (-4.42%) ▼|RTX215.25-3.33 (-1.52%) ▼|SBUX104.14+1.04 (+1.01%) ▲|SCHW104.47-1.50 (-1.42%) ▼|SO96.05-0.73 (-0.75%) ▼|SPG235.61-1.09 (-0.46%) ▼|T23.94-0.72 (-2.92%) ▼|TMO576.46+0.05 (+0.01%) ▲|TMUS181.52-0.87 (-0.48%) ▼|TSLA298.32-9.12 (-2.97%) ▼|TXN271.30-5.77 (-2.08%) ▼|UBER71.20+0.46 (+0.65%) ▲|UNH420.57-8.22 (-1.92%) ▼|UNP292.19-2.26 (-0.77%) ▼|UPS104.56-0.97 (-0.92%) ▼|USB62.82-1.61 (-2.50%) ▼|V368.73+2.14 (+0.58%) ▲|VZ47.22-0.97 (-2.01%) ▼|WFC83.87-3.00 (-3.45%) ▼|WMT114.22+1.12 (+0.99%) ▲|XOM156.75+3.71 (+2.42%) ▲|
27.3 C
New York
Wednesday, July 29, 2026

Tag: trials

newssourceFORcompanyinformationcontent1releasesmarket

Immunic to Participate in Investor, Industry and Scientific Conferences in June

NEW YORK, June 10, 2026 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases,...

SingPost Unveils S$30 Million Automated Sortation Hub, Announces Islandwide Rollout of ‘SingPost@MyBlock’

Dual initiatives advance Group strategy by tripling parcel processing capacity to lower cost-to-serve and enhancing public convenienceSINGAPORE, June 10, 2026 /PRNewswire/ -- Singapore Post...

Antengene Receives IND Approval for ATG-201 (CD19 × CD3 TCE) in Autoimmune Disease in China

SHANGHAI and HONG KONG, June 10, 2026 /PRNewswire/ -- Antengene Corporation Limited  ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to...

Lynk Pharmaceuticals’ Partner Formation Bio Doses First Participant in Phase 1 Trial of BLKR201 (originally designated as LNK01006), a CNS-Penetrant TYK2 Inhibitor

HANGZHOU, China, SHANGHAI and BOSTON, June 10, 2026 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on...

FDA approves Lilly’s EBGLYSS® (lebrikizumab-lbkz) for one maintenance dose every eight weeks in patients with moderate-to-severe atopic dermatitis

EBGLYSS is now the only approved option that offers as few as six maintenance injections per year with no required topicals from the startINDIANAPOLIS,...

Cellectis Receives FDA RMAT Designation for lasme-cel, the First Allogeneic CAR-T Therapy in a Pivotal Trial for Patients with r/r B-ALL

NEW YORK, June 09, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to lasmecabtagene timgedleucel (lasme-cel), its CD22-targeting allogeneic CAR-T cell therapy product candidate, for the treatment of patients with relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL).

Tevogen Announces Formation of a Healthcare Services Initiative

Tevogen launches Healthcare Services initiative to evaluate MSO and CRO acquisitions with potential to support approximately $100M in annual revenue.

Longeveron Granted Small or Medium-sized Enterprise (SME) Status by the European Medicines Agency (EMA)

Longeveron (LGVN) granted Small or Medium-sized Enterprise (SME) status by the European Medicines Agency (EMA).

Actuate Therapeutics’ Elraglusib Selected for Evaluation in BEACON2 Trial for High-Risk Pediatric Neuroblastoma

- BEACON2 is a landmark European multi-arm, multi-stage Phase 1/2 platform trial conducted and sponsored by the Cancer Research UK Clinical Trials Unit (CRCTU), University of Birmingham 

- Elraglusib will be assessed in combination with dinutuximab beta plus chemotherapy in patients with relapsed and refractory neuroblastoma

- Complete response in neuroblastoma patient achieved in Phase 1 study of elraglusib in refractory pediatric cancers

BioPorto initiates U.S. Adult Validation Study following U.S. Food and Drug Administration (FDA) feedback

June 9, 2026
Announcement no. 12

MDP Enters OLIVE YOUNG

MDP launched four key SKUs at OLIVE YOUNG Pasadena, which opened on May 29. Additional rollout planned for the upcoming OLIVE YOUNG Century City...

Harness Therapeutics Awarded Grant from The Michael J. Fox Foundation for Parkinson’s Research to Advance Parkinson’s Disease Programme

Grant awarded through the Parkinson's Disease Therapeutics Pipeline Program to support advancement of Harness' new programme targeting GCase and LIMP2 for Parkinson's disease

Exilby® Receives First European Marketing Authorization as VERTANICAL Prepares UK Submission for its First-in-Class Non-Opioid Treatment for Chronic Low Back Pain

GRÄFELFING, Germany, June 9, 2026 /PRNewswire/ -- VERTANICAL today announced that Exilby® (VER-01) has received marketing authorization in Germany for the treatment of chronic...

IDEAYA Announces Pricing of $300 Million Offering of Common Stock and Pre-Funded Warrants

SOUTH SAN FRANCISCO, Calif., June 8, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA) today announced the pricing of an underwritten public offering of common...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsTrials

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers